Waters and Andrews Alliance Sign Co-Marketing Agreement
Waters Corporation (NYSE:WAT) and Andrew Alliance today announced they have signed an agreement that will bring drug development scientists an easy-to-use, semi-automated sample preparation approach for released N-glycan profiling and analysis by LC and LC-MS. Under the co-marketing agreement, Waters will combine its existing Glycoworks™ RapiFluor-MS™ (RFMS) N-Glycan Kits with an Andrew pipetting robot that will allow laboratories to meet the demands on them for glycan profiling while improving the accuracy and precision of LC and LC-MS results.
